Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Debarment for criminal companies?

This article was originally published in The Gray Sheet

Executive Summary

FDA should have the authority to kick criminal medical device companies and involved individuals out of the regulatory process, a Feb. 11 staff report from House Energy and Commerce Committee ranking member Joe Barton, R-Texas, says. Presently, only companies or individuals from the generic drug industry can be debarred if they are convicted of bribery, fraud, perjury or other crimes related to the FDA regulatory process. The report says the debarment provisions in the Generic Drug Enforcement Act, originally passed more than 15 years ago, should also extend to biologic, name-brand drug and animal drug companies. FDA has only used its debarment authority nine times, and has never debarred a company

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025778

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel